Barclays analyst Gena Wang lowered the firm’s price target on BioCryst to $10 from $12 and keeps an Equal Weight rating on the shares after the company announced discontinuation of its lead candidate in paroxysmal nocturnal hemoglobinuria and shifted focus to new Factor D inhibitor BCX10013. The analyst is not surprised by the news.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- Oppenheimer keeps Perform on BioCryst after discontinuation of BCX9930 program
- Cowen says full sale of BioCryst ‘potentially now even more likely’
- BioCryst discontinuation should surprise no one, says Piper Sandler
- BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
- BioCryst discontinues development of BCX9930, shifts focus to BCX10013